Riverside Partnership in Ultra Secure Defense Hardware Could Be A Game Changer For Plexus (PLXS)

• In May 2026, Riverside Research announced a partnership with Plexus Corp. to co-develop reusable modular hardware and software for ultra-secure, connected devices serving intelligence and defense customers, debuting the Aegis R52L Enhanced Retransmission Device after moving from concept to full-scale manufacturing plans in under nine months.
• This collaboration highlights Plexus’s ability to combine rapid prototyping with complex, regulated-market manufacturing, potentially strengthening its position in high-security defense and intelligence applications.
• Next, we’ll examine how this rapid-prototyping partnership in ultra-secure defense hardware and software may influence Plexus’s existing investment narrative.

Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

Plexus Investment Narrative Recap

To own Plexus, you need to believe in its ability to win and execute complex, high-value manufacturing programs across healthcare, industrial and aerospace/defense, while managing margin pressure and customer concentration. The Riverside Research partnership reinforces Plexus’s role in ultra-secure defense hardware, which may support the current growth catalyst of expanding high-complexity defense work, but it does not fundamentally change the near-term risks around sector cyclicality and large-program timing.

Among recent announcements, the Q2 FY2026 results and Q3 guidance stand out alongside this defense news. Revenue of US$1,163.76 million and GAAP diluted EPS of US$1.82, with Q3 revenue guided to US$1,200 million to US$1,250 million, give investors a clearer base from which to judge how much incremental value partnerships like Riverside and earlier wins such as Evolv Technologies might add to Plexus’s program pipeline and utilization in the coming quarters.

Yet behind this progress, investors should be aware that revenue concentration and large contract ramp risks could...

Read the full narrative on Plexus (it's free!)

Plexus' narrative projects $5.4 billion revenue and $223.8 million earnings by 2029. This requires 9.4% yearly revenue growth and about a $47 million earnings increase from $176.8 million today.

Uncover how Plexus' forecasts yield a $210.80 fair value, a 21% downside to its current price.

Exploring Other Perspectives

While consensus focuses on steady growth, the most optimistic analysts were already modeling revenues near US$5,200 million and earnings of about US$257 million by 2029, assuming aerospace and defense wins keep ramping, so this new ultra secure defense partnership could eventually push you to reconsider which scenario feels more realistic.

Explore 2 other fair value estimates on Plexus - why the stock might be worth 42% less than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Plexus research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Plexus research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Plexus' overall financial health at a glance.

Contemplating Other Strategies?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 13 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com